Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
nonalcoholic steatohepatitis (NASH)
Pharma
Novo Nordisk's semaglutide delivers in phase 3 MASH study
With a positive readout for MASH now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semaglutide.
Fraiser Kansteiner
Nov 1, 2024 10:38am
Madrigal's MASH drug Rezdiffra 'blew away' expectations in Q3
Oct 31, 2024 3:24pm
Lilly, Gilead-Yuhan, Leqembi—Fierce Pharma Asia
Oct 18, 2024 8:20am
Madrigal maps out 'Way Forward' for MASH patients with Rezdiffra
Sep 6, 2024 6:30am
With FDA nod for Iqirvo, Ipsen and Genfit will take on Intercept
Jun 11, 2024 11:07am
Madrigal builds launch infrastructure for MASH drug Rezdiffra
May 7, 2024 11:56am
